AbbVie is a drug giant selling blockbuster meds for arthritis, psoriasis, cancer, and more—think of it as a pharmacy shelf with a few superstars.
Money flows from patented drugs like HUMIRA and SKYRIZI, with gross margins around 74% and recurring prescription sales.
Patents and complex biologics keep copycats out, but HUMIRA faces biosimilar competition from Amgen and others, eroding its dominance.
Hold (sector percentile 63) — value C+, growth A-, profitability C-, momentum B, revisions B+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Analyst upgrade signals positive outlook, may boost sentiment
Large M&A financing may impact leverage; dividend sustainability in focus
Bill Few cuts 9.4%, BDF Gestion cuts 10.1%
Q2 rev ~$17B +10.2% YoY; Skyrizi +24% to $5.5B; FY rev view raised $300M to ~$67.6B; adj EPS cut to ~$13.8
Skyrizi and Rinvoq keep driving growth as acquisition-related expenses reshape the earnings outlook.
First systemic vitiligo drug approved in EU; stock hits 52-week high, reflecting positive market response
Multiple sources confirm 52-week highs, focus ahead of Q2 earnings
ABN Amro +80.6%, Andra AP +44.2%, Baader Bank +560.7%, continuing institutional stake changes.
Deal funded with debt, leaving cash intact; dividend program expected to continue.
Q1 2026 adjusted EPS of $2.65, $0.07 above guidance midpoint; full year guidance raised to $14.08-$14.28 (increase of $0.12)
None yet
None yet
AbbVie is a top holding in the iShares Core Dividend Growth ETF, indicating its inclusion in a dividend-focused investment strategy. The discussion is about ETF holdings.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
